American Society of Hirudotherapy

Chronic Pruritus of Unknown Origin (Investigational Adjunct)

Investigational adjunct for chronic pruritus of unknown origin after systemic workup; antihistamines, gabapentinoids, and (for select cases) systemic immunomodulators remain evidence-based.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for chronic pruritus of unknown origin. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
What evidence exists?
Tier C (investigational). No clinical study of leech therapy for chronic pruritus of unknown origin was identified, so its effect is unknown. Evidence-based first-line management is thorough workup for systemic causes (renal, hepatic, hematologic including polycythemia vera, thyroid, HIV, malignancy), skin examination for subtle dermatosis, emollients and antihistamines, gabapentin or pregabalin for neuropathic itch, antidepressants (mirtazapine, SSRIs) for chronic itch, dupilumab in select cases, and phototherapy.
Main risks
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Itch worsening from new bite sites adding to cutaneous inflammation
  • Delaying systemic workup that may identify treatable cause (lymphoma, polycythemia vera, cholestasis)
Who should not consider this
  • Patients without comprehensive systemic workup (CBC, comprehensive metabolic panel, TSH, HIV, age-appropriate cancer screening)
  • Patients with red-flag findings (weight loss, lymphadenopathy, night sweats) needing oncology workup
  • Patients who have not tried antihistamines, gabapentinoids, and skin care
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with anemia
  • People with an active infection at the planned application site
What to ask your clinician
  • Have I had a full workup for systemic causes of itch?
  • Has age-appropriate cancer screening been completed (chronic itch can be a paraneoplastic symptom)?
  • Have I tried antihistamines, gabapentin, and an antidepressant such as mirtazapine?
  • Have phototherapy and dupilumab been considered?
  • What is the published evidence base for leeches in idiopathic chronic pruritus?
  • What is the plan if workup later reveals a systemic cause?
When to seek urgent care
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Unintentional weight loss, night sweats, swollen lymph nodes, or new fatigue (possible underlying malignancy)
  • Yellowing of the skin or eyes, dark urine, or pale stools (possible liver disease)

What this does NOT mean

  • It does not mean leech therapy is FDA-cleared for chronic pruritus — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace systemic workup, which is the cornerstone of unexplained chronic itch.
  • It does not treat underlying causes (cholestasis, polycythemia, lymphoma) that produce itch.
  • It does not have RCT evidence in this indication; no clinical study of leech therapy for chronic pruritus of unknown origin was identified.
  • It may delay diagnosis of a serious underlying condition.

Clinical Profile

Category
Dermatological
ICD-10
L29.9, L29.8
Safety tier
Low

Evidence Summary

Chronic pruritus is defined as itch lasting more than 6 weeks. Chronic pruritus of unknown origin (CPUO) is a diagnosis after thorough workup excludes primary dermatologic disease, systemic causes (renal, hepatic, hematologic, endocrine, malignancy, drug-induced), and neuropathic and psychogenic etiologies. Evidence-based management includes emollients, sedating antihistamines (mainly for sleep), gabapentinoids, mirtazapine, naltrexone, narrow-band UVB phototherapy, and emerging biologics. No clinical study or case report of hirudotherapy for chronic pruritus of unknown origin was identified in PubMed, Europe PMC, Crossref or Russian- and German-language sources as of October 2026. The nearest leech data are small open-label eczema studies (Shankar 2014, 27 patients; Ulla P 2025, 20 patients), a different condition.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Incomplete systemic workup (rule out malignancy, renal, hepatic, hematologic causes first)
  • Active excoriations or infected skin
  • Psychogenic itch as primary diagnosis (refer to psychiatry)
  • Severe atopic dermatitis where dupilumab is indicated

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.